Dr. Mark A. Slabaugh, M.D.
Ophthalmology (Glaucoma Specialist (Ophthalmology) Physician)
- Medicare participating
At a glance
- Medical school
- University of Washington School of Medicine (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 721
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: University of Washington School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Glaucoma Specialist (Ophthalmology) Physician primary
OH license 35123143 -
Ophthalmology Physician
OH license 35123143
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohio State University State Health System Columbus, OH
Medical groups
- Osu Eye Physicians and Surgeons, LLC (47 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 721
- Services billed
- 2,315
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 727 | 467 |
| Imaging of optic nerve | 298 | 282 |
| Established patient office or other outpatient visit, 20-29 minutes | 217 | 156 |
| Measurement of corneal curvature and depth of eye | 184 | 106 |
| Exam of visual field with extended testing | 166 | 158 |
| New patient office or other outpatient visit, 45-59 minutes | 152 | 152 |
| Removal of cataract with insertion of prosthetic lens | 101 | 68 |
| Imaging of retina | 78 | 56 |
| Complex removal of cataract with insertion of prosthetic lens | 63 | 44 |
| Removal of recurring cataract in lens capsule using a laser | 47 | 42 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Latanoprost Other prescribers in Columbus, OH | 871 |
| Prednisolone Acetate Other prescribers in Columbus, OH | 522 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Columbus, OH | 358 |
| Timolol Maleate Other prescribers in Columbus, OH | 302 |
| Ketorolac Tromethamine Other prescribers in Columbus, OH | 196 |
| Brimonidine Tartrate Other prescribers in Columbus, OH | 149 |
| Fluorometholone Other prescribers in Columbus, OH | 68 |
| Lumigan (bimatoprost) Other prescribers in Columbus, OH | 65 |
| Ofloxacin Other prescribers in Columbus, OH | 63 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Columbus, OH | 45 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 1 companies. The companies reported $19,824 in research payments for these studies, mostly to the institutions running them.
- SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
AbbVie Inc. - Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
AbbVie Inc. - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor
AbbVie Inc. · Completed · NCT05216250 - AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
AbbVie Inc. · Active, not recruiting · NCT04499248 - AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.